SE9903995D0 - New combination - Google Patents

New combination

Info

Publication number
SE9903995D0
SE9903995D0 SE9903995A SE9903995A SE9903995D0 SE 9903995 D0 SE9903995 D0 SE 9903995D0 SE 9903995 A SE9903995 A SE 9903995A SE 9903995 A SE9903995 A SE 9903995A SE 9903995 D0 SE9903995 D0 SE 9903995D0
Authority
SE
Sweden
Prior art keywords
new combination
active ingredient
beta2
beta
kit
Prior art date
Application number
SE9903995A
Other languages
English (en)
Inventor
Jan Trofast
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9903995A priority Critical patent/SE9903995D0/sv
Publication of SE9903995D0 publication Critical patent/SE9903995D0/sv
Priority to AU16526/01A priority patent/AU1652601A/en
Priority to EP00975117A priority patent/EP1242065A1/en
Priority to PCT/SE2000/002115 priority patent/WO2001032163A1/en
Priority to PCT/SE2000/002116 priority patent/WO2001032166A1/en
Priority to CA002388657A priority patent/CA2388657A1/en
Priority to CN00815363A priority patent/CN1387431A/zh
Priority to AU13214/01A priority patent/AU1321401A/en
Priority to KR1020027005683A priority patent/KR20020050254A/ko
Priority to JP2001534368A priority patent/JP2003513037A/ja
Priority to MXPA02004334A priority patent/MXPA02004334A/es
Priority to BR0015172-6A priority patent/BR0015172A/pt
Priority to IL14936500A priority patent/IL149365A0/xx
Priority to ZA200203178A priority patent/ZA200203178B/xx
Priority to NO20022103A priority patent/NO20022103L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
SE9903995A 1999-11-03 1999-11-03 New combination SE9903995D0 (sv)

Priority Applications (15)

Application Number Priority Date Filing Date Title
SE9903995A SE9903995D0 (sv) 1999-11-03 1999-11-03 New combination
IL14936500A IL149365A0 (en) 1999-11-03 2000-10-27 NEW COMBINATION COMPRISING A BETA 2(β)2 ADRENO RECEPTOR AGONIST AND A LEUKOTRIENE RECEPTOR ANTAGONIST
CN00815363A CN1387431A (zh) 1999-11-03 2000-10-27 新的包含β2肾上腺受体激动剂和白三烯受体拮抗剂的组合物
KR1020027005683A KR20020050254A (ko) 1999-11-03 2000-10-27 베타 2 (β2) 아드레날린 수용체 작용제 및 류코트리엔수용체 길항제를 포함하는 신규한 조합물
PCT/SE2000/002115 WO2001032163A1 (en) 1999-11-03 2000-10-27 NEW COMBINATION COMPRISING A BETA 2 (β)2 ADRENO RECEPTOR AGONIST AND A LENKOTRIENE RECEPTOR ANTAGONIST
PCT/SE2000/002116 WO2001032166A1 (en) 1999-11-03 2000-10-27 NEW COMBINATION COMPRISING A β2-ADRENORECEPTOR AGONIST AND A LEUKOTRIENE RECEPTOR ANTAGONIST
CA002388657A CA2388657A1 (en) 1999-11-03 2000-10-27 New combination comprising a beta 2 (.beta.)2 adreno receptor agonist and a leukotriene receptor antagonist
AU16526/01A AU1652601A (en) 1999-11-03 2000-10-27 New combination comprising a beta2-adrenoreceptor agonist and a leukotriene receptor antagonist
AU13214/01A AU1321401A (en) 1999-11-03 2000-10-27 New combination comprising a beta 2 (beta)2 adreno receptor agonist and a leukotriene receptor antagonist
EP00975117A EP1242065A1 (en) 1999-11-03 2000-10-27 New combination comprising a beta 2 (beta)2 adreno receptor agonist and a leukotriene receptor antagonist
JP2001534368A JP2003513037A (ja) 1999-11-03 2000-10-27 β２（β２）アドレノレセプターアゴニストとロイコトリエンアンタゴニストを含む新規組合せ
MXPA02004334A MXPA02004334A (es) 1999-11-03 2000-10-27 Nueva combinacion que comprende un agonista de adrenorreceptores veta 2 y un antagonista de receptores de leucotrieno.
BR0015172-6A BR0015172A (pt) 1999-11-03 2000-10-27 Nova combinação compreendendo um agonista adreno receptor de beta 2 (beta 2) e um antagonista receptor de leucotrieno
ZA200203178A ZA200203178B (en) 1999-11-03 2002-04-22 New combination comprising a beta 2 (beta)2 adreno receptor agonist and a leukotriene receptor antagonist.
NO20022103A NO20022103L (no) 1999-11-03 2002-05-02 Ny kombinasjon innbefattende en beta 2 (<beta>)2 andrenore- septoragonist og leukotrienreseptorantagonist

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9903995A SE9903995D0 (sv) 1999-11-03 1999-11-03 New combination

Publications (1)

Publication Number Publication Date
SE9903995D0 true SE9903995D0 (sv) 1999-11-03

Family

ID=20417605

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9903995A SE9903995D0 (sv) 1999-11-03 1999-11-03 New combination

Country Status (13)

Country Link
EP (1) EP1242065A1 (sv)
JP (1) JP2003513037A (sv)
KR (1) KR20020050254A (sv)
CN (1) CN1387431A (sv)
AU (2) AU1321401A (sv)
BR (1) BR0015172A (sv)
CA (1) CA2388657A1 (sv)
IL (1) IL149365A0 (sv)
MX (1) MXPA02004334A (sv)
NO (1) NO20022103L (sv)
SE (1) SE9903995D0 (sv)
WO (2) WO2001032166A1 (sv)
ZA (1) ZA200203178B (sv)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
PE20050130A1 (es) * 2002-08-09 2005-03-29 Novartis Ag Compuestos organicos
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
GB0315889D0 (en) 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
CA2562009A1 (en) * 2004-04-05 2005-10-20 Sepracor Inc. (r,r)-formoterol in combination with other pharmacological agents
ES2245612B1 (es) * 2004-06-29 2007-08-16 Universidad De Barcelona Nuevo uso terapeutico del formoterol.
MX2007011273A (es) * 2005-03-16 2007-11-08 Meda Pharma Gmbh & Co Kg La combinacion de anticolinergicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias.
CN103562185A (zh) 2011-06-06 2014-02-05 奇斯药制品公司 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烷基醇的衍生物
CA2893628C (en) * 2012-12-05 2021-11-30 Chiesi Farmaceutici S.P.A. 1-phenyl-2-pyridinyl alkyl alcohol derivatives as phosphodiesterase inhibitors
JP5846185B2 (ja) 2013-11-21 2016-01-20 大日本印刷株式会社 貫通電極基板及び貫通電極基板を用いた半導体装置
PT109030B (pt) * 2015-12-15 2019-09-25 Hovione Farmaciência, S.A. Preparação de partículas inaláveis de zafirlucaste

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604752D0 (sv) * 1996-12-20 1996-12-20 Astra Ab Formulation and use
JP2001514660A (ja) * 1997-03-13 2001-09-11 メルク エンド カンパニー インコーポレーテッド キノリンロイコトリエン拮抗薬
SE9704644D0 (sv) * 1997-12-12 1997-12-12 Astra Ab New use

Also Published As

Publication number Publication date
IL149365A0 (en) 2002-11-10
JP2003513037A (ja) 2003-04-08
AU1321401A (en) 2001-05-14
CA2388657A1 (en) 2001-05-10
MXPA02004334A (es) 2002-11-07
AU1652601A (en) 2001-05-14
WO2001032163A1 (en) 2001-05-10
NO20022103D0 (no) 2002-05-02
EP1242065A1 (en) 2002-09-25
BR0015172A (pt) 2002-06-18
KR20020050254A (ko) 2002-06-26
CN1387431A (zh) 2002-12-25
NO20022103L (no) 2002-05-02
ZA200203178B (en) 2003-07-22
WO2001032166A1 (en) 2001-05-10

Similar Documents

Publication Publication Date Title
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
EE200300524A (et) Ühendid, mis on CB2-retseptori agonistid, neid sisaldavad ravimkoostised ja nimetatud ühendite kasutamine ravis
DK0668863T3 (da) Quinuclidinderivat som substans P-antagonist
HUP0203586A2 (hu) Szerotonin újrafelvétel inhibitorának, valamint 5-ht2c antagonistának, inverz agonistának vagy részleges agonistának a kombinációja
DK1135153T3 (da) Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser
MXPA03000548A (es) Combinacion novedosa de agonista (5-ht2) y antagonistas (5-ht6) de serotonina como formulacion farmaceutica.
AR025883A1 (es) Utilizacion de antagonistas de los receptores de los cannabinoides centrales para la preparacion de medicamentos
HUP0203590A2 (hu) Gyógyszerkészítmény a csonttömeg csökkenésével járó betegségek kezelésére
MXPA06002722A (es) Composicion farmaceutica que comprende un antagonista del receptor p2x7 y un farmaco anti-inflamatorio no esteroidal.
SE9903995D0 (sv) New combination
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
NO20020574D0 (no) Substituerte 1,5-dihydropyrrol-2-onderivater som er virksomme som NMDA-reseptorantagonister for behandlingen av smertetilstanden
BG105256A (en) Muscarinic agonists and antagonists
DK1104289T3 (da) Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister
AU4179399A (en) Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders
SE9902935D0 (sv) Pharmaceutical compositions
EE05211B1 (et) Saredutandi ja selle farmatseutiliselt vastuv?etavate soolade kasutamine meeleoluh„irete, kohanemish„irete v?i segatpi „rev-depressiivsete h„irete raviks v?i v„ltimiseks kasulike ravimite valmistamiseks
HUP0002346A1 (hu) Emlősök elmezavarainak kezelésére szolgáló gyógyszerkészítmény
EE200100520A (et) N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena
SE0300445D0 (sv) New combination
BG106548A (en) Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog
EE200100689A (et) IL6RIL6 kimääri kasutamine ravimi valmistamiseks,mis on ette nähtud neuroloogiliste haiguste ravimiseks, ning farmatseutiline kompositsioon
SE0001916D0 (sv) Novel formulation
BR9812531A (pt) Combinação de componentes, preparação farmacêutica, produção desta, e, uso da combinação ou da preparação farmacêutica
BR0000486A (pt) Antagonistas do neuropeptìdeo y